tirzepatide and glaucoma Linked to Lower Risk in Type 2 Diabetes Compared to Other Weight Loss Drugs: Study Tirzepatide is Associated With Reduced

Recent studies have shown that Mounjaro, a once-weekly injectable drug approved to treat type 2 diabetes, can also provide significant weight loss benefits to people who are obese

The reviewer could not verify media endorsement claims (logos from the New York Times, Healthline, and Fortune displayed on the website)

The emphasis was on recent and clinically relevant evidence, particularly phase III trials and contemporary meta-analyses that inform translational and hybrid lifestylepharmacologic approaches

[10] Its administration during pregnancy carries potential risks to fetal development, and it is not indicated for use once pregnancy is confirmed